Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

Rhea-AI Summary

Context Therapeutics (Nasdaq: CNTX) announced that the FDA granted Fast Track Designation to CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, for treatment of platinum-resistant ovarian cancer (PROC).

CTIM-76 is in a Phase 1 trial evaluating safety, tolerability, pharmacokinetics and anti-tumor activity in CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers. The company expects interim Phase 1a data in June 2026.

Positive

• FDA Fast Track granted for CTIM-76 in PROC
• Interim Phase 1a data expected by June 2026
• CTIM-76 targets CLDN6-positive advanced or metastatic tumors

Negative

• CTIM-76 remains in Phase 1, reflecting early-stage clinical risk
• No efficacy or approval yet; clinical benefit not established

News Market Reaction – CNTX

+2.64%

8 alerts

+2.64% Session close to close

$271.03M Market Cap

0.4x Rel. Volume

In the Apr 2 session, CNTX gained 2.64%, reflecting a moderate positive market reaction. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights FDA Fast Track Designation for CTIM-76 in platinum-resistant ovarian ca...

Analysis

This announcement highlights FDA Fast Track Designation for CTIM-76 in platinum-resistant ovarian cancer, reinforcing the program’s potential in an area of significant unmet need. It builds on earlier Phase 1 trial initiations across the portfolio and points toward an interim CTIM-76 data readout in June 2026. Investors may track future updates on safety, overall response rate, duration of response and disease control rate as key markers of clinical and regulatory progress.

Key Figures

Interim data timing: June 2026 Trial phase: Phase 1a Indication: Platinum-resistant ovarian cancer

3 metrics

Interim data timing June 2026 CTIM-76 Phase 1a interim data expected

Trial phase Phase 1a Ongoing CTIM-76 clinical trial

Indication Platinum-resistant ovarian cancer Fast Track Designation treatment setting

Previous Clinical trial Reports

2 past events · Latest: Apr 09 (Positive)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 09	CT-95 Phase 1 start	Positive	+0.1%	First dosing in Phase 1 CT-95 trial with initial data targeted mid-2026.
Jan 14	CTIM-76 Phase 1 start	Positive	-1.0%	First patient dosed in CTIM-76 Phase 1 trial for CLDN6-positive tumors.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clinical trial initiations have triggered small and mixed price reactions around flat.

Recent Company History

Recent updates show steady pipeline execution across CTIM-76, CT-95 and CT-202. Prior clinical trial milestones, such as first-patient-dosed events in January 2025 and April 2025, produced modest share moves near flat. The current Fast Track Designation builds on that history of advancing CD3 bispecifics in difficult solid tumors and follows guidance that CTIM-76 Phase 1a interim data are expected in June 2026, reinforcing the program’s regulatory and clinical momentum.

Key Terms

fast track designation, t cell engaging, bispecific antibodies, cldn6, +4 more

8 terms

fast track designation regulatory

"the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation to CTIM-76"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

t cell engaging medical

"a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies"

T cell engaging describes a type of immunotherapy that directs a patient’s T cells—immune cells that kill infected or abnormal cells—to recognize and attack disease cells by physically linking or activating them, like a matchmaker bringing two parties together to get a job done. Investors monitor these therapies because they can offer strong, targeted clinical effects and commercial upside, but they also involve safety risks, complex manufacturing and tight regulatory review that influence development timelines and returns.

bispecific antibodies medical

"advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors"

Engineered proteins that can attach to two different biological targets at once, like a two-headed key that fits two locks simultaneously; in medicine they often link immune cells to diseased cells or block two disease pathways at the same time. Investors care because this dual-action design can improve effectiveness or open new treatment options, but it also raises development complexity, manufacturing cost and regulatory risk, affecting a biotech company’s value and partnerships.

cldn6 medical

"CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody"

CLDN6 is a gene that makes a protein called claudin-6, which sits on the surface of some cells and helps seal the gaps between them like grout between tiles. Investors watch it because claudin-6 can act as a clear target or marker for cancer drugs and tests — if a therapy can specifically find and bind this protein, it may treat tumors more precisely, affecting a drug’s potential market value and development risk.

cd3 medical

"CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody"

CD3 is a group of proteins on the surface of T cells, the immune system’s front-line soldiers, that act like a control panel to turn those cells on and off. It matters to investors because many modern therapies work by engaging or blocking CD3 to direct T cells against cancer or dampen harmful immune reactions; success, safety and regulatory approval of CD3-targeting drugs can significantly affect a biotech company’s prospects.

overall response rate medical

"anti-tumor activity by overall response rate, duration of response and disease control rate"

Overall response rate is the percentage of patients in a clinical study whose measurable disease shrinks or disappears after receiving a treatment. Investors watch it like a product’s “hit rate” because higher response rates can signal a drug’s effectiveness, boost chances of regulatory approval and market demand, and affect a company’s future revenue prospects, similar to how a higher batting average suggests a more reliable player.

duration of response medical

"anti-tumor activity by overall response rate, duration of response and disease control rate"

Duration of response is the length of time a patient’s condition stays improved after a treatment until it starts to worsen again; think of it as how long a freshly charged battery continues to power a device. For investors, longer duration of response implies a treatment provides sustained benefit, which can boost a drug’s commercial value, support stronger regulatory labeling and payer coverage, and reduce the need for additional therapies.

disease control rate medical

"anti-tumor activity by overall response rate, duration of response and disease control rate"

The disease control rate is the share of patients in a clinical trial whose cancer or condition either shrinks or stops getting worse for a specified period after treatment. Think of it like the percentage of people for whom a treatment hits pause or nudges back the problem rather than letting it progress; higher rates suggest the therapy can meaningfully limit disease, which matters to investors assessing a drug’s potential efficacy and commercial value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC

CTIM-76 Phase 1a trial ongoing, with interim data expected in June 2026

PHILADELPHIA, April 02, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation to CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, for the treatment of platinum-resistant ovarian cancer (“PROC”) in patients that have received all standard of care therapies.

Context is currently evaluating CTIM-76 in a Phase 1 clinical trial designed to evaluate the safety and efficacy of CTIM-76 in subjects with CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers. The dose escalation and dose expansion portions of the trial are expected to evaluate safety, tolerability and pharmacokinetics, as well as anti-tumor activity by overall response rate, duration of response and disease control rate.

“We are pleased to receive Fast Track Designation for CTIM-76, which underscores its potential to improve the lives of patients with platinum-resistant ovarian cancer,” said Karen Chagin, M.D., Chief Medical Officer of Context. “This designation is an important step forward in our goal to quickly and efficiently advance CTIM-76 through clinical development and we look forward to sharing interim data for this program in June 2026.”

The FDA’s Fast Track Designation program is designed to expedite the development and review timelines of drugs that demonstrate the potential to treat serious conditions, aiming to deliver therapeutics to patients more quickly in areas of unmet need.

About CTIM-76
CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. CLDN6 is enriched in a wide range of solid tumors, including ovarian, endometrial, lung, gastric and testicular. Preclinical research suggests the potential for convenient dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for CTIM-76 therapy. More information about the CTIM-76 clinical trial (NCT06515613) can be found on https://clinicaltrials.gov/.

About Context Therapeutics^®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context’s goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 TCE, CT-95, a Mesothelin x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.

Forward-looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the Company’s expectation to provide Phase 1a interim data for CTIM-76 in June 2026, (ii) the potential benefits, characteristics, safety and side effect profile of the Company’s product candidates, (iii) the likelihood data will support future development, and (iv) the likelihood of obtaining regulatory approval of the Company’s product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and the Company therefore cannot assure the reader that its plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

Investor Relations Contact:
Jennifer Minai-Azary
Chief Financial Officer
Context Therapeutics
IR@contexttherapeutics.com

FAQ

What does FDA Fast Track for CTIM-76 mean for Context Therapeutics (CNTX)?

Fast Track speeds development and review for drugs addressing serious unmet needs. According to Context, Fast Track for CTIM-76 aims to expedite its clinical evaluation and regulatory dialogue for PROC.

When will Context Therapeutics (CNTX) report interim data for CTIM-76?

Interim Phase 1a data are expected in June 2026. According to Context, the company plans to share preliminary safety and activity data from the ongoing trial then.

What indication is CTIM-76 targeting in the Phase 1 trial for CNTX?

CTIM-76 targets platinum-resistant ovarian cancer (PROC) and other CLDN6-positive tumors. According to Context, the trial includes ovarian, endometrial and testicular cancers with CLDN6 expression.

What endpoints is the CTIM-76 Phase 1 trial evaluating for Context Therapeutics (CNTX)?

The trial will assess safety, tolerability, pharmacokinetics and anti-tumor activity. According to Context, anti-tumor measures include overall response rate, duration of response and disease control rate.

Does Fast Track designation mean CTIM-76 is approved for PROC for CNTX?

No, Fast Track is not approval; it expedites review and development processes. According to Context, CTIM-76 remains investigational and is undergoing Phase 1 evaluation.